Factors Associated with Liver Fibrosis in Chinese Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease

References

• Lindekilde N, Scheuer SH, Rutters F, et al. Prevalence of type 2 diabetes in psychiatric disorders: an umbrella review with meta-analysis of 245 observational studies from 32 systematic reviews. Diabetologia. 2022;65(3):440–456. doi:10.1007/s00125-021-05609-x
   PubMed Web of Science ®Google Scholar
• Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management. Endocr Rev. 2020;41(1). doi:10.1210/endrev/bnz009
   PubMed Web of Science ®Google Scholar
• Kim GA, Lee HC, Choe J, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol. 2017. doi:10.1016/j.jhep.2017.09.012
   Google Scholar
• Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557–1565. doi:10.1002/hep.29085
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. doi:10.1016/j.jhep.2019.06.021
   PubMed Web of Science ®Google Scholar
• Chun HS, Lee JS, Lee HW, et al. Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes. J Gastroenterol Hepatol. 2021;36(6):1703–1713. doi:10.1111/jgh.15387
   PubMed Web of Science ®Google Scholar
• Saito H, Tanabe H, Kudo A, et al. High FIB4 index is an independent risk factor of diabetic kidney disease in type 2 diabetes. Sci Rep. 2021;11(1):11753. doi:10.1038/s41598-021-88285-6
   PubMed Web of Science ®Google Scholar
• Kim K, Oh TJ, Cho HC, et al. Liver fibrosis indices are related to diabetic peripheral neuropathy in individuals with type 2 diabetes. Sci Rep. 2021;11(1):24372. doi:10.1038/s41598-021-03870-z
   PubMed Web of Science ®Google Scholar
• Zhu X, Yan H, Chang X, et al. Association between non-alcoholic fatty liver disease-associated hepatic fibrosis and bone mineral density in postmenopausal women with type 2 diabetes or impaired glucose regulation. BMJ Open Diabetes Res Care. 2020;8(1):e000999. doi:10.1136/bmjdrc-2019-000999
   PubMed Web of Science ®Google Scholar
• Tacke F, Weiskirchen R. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. Ann Transl Med. 2021;9(8):729. doi:10.21037/atm-20-4354
   PubMed Web of Science ®Google Scholar
• Ciardullo S, Monti T, Perseghin G. High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes. Diabetes Care. 2021;44(2):519–525. doi:10.2337/dc20-1778
   PubMed Web of Science ®Google Scholar
• Yao VJH, Sun M, Rahman AA, et al. Comparative analysis of metabolic risk factors for progression of non-alcoholic fatty liver disease. Clin Exp Hepatol. 2021;7(2):241–247. doi:10.5114/ceh.2021.107567
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Pham H, Felix S, et al. Identification of high-risk patients with nonalcoholic fatty liver disease using noninvasive tests from primary care and endocrinology real-world practices. Clin Transl Gastroenterol. 2021;12(4):e00340. doi:10.14309/ctg.0000000000000340
   PubMed Web of Science ®Google Scholar
• Mansour A, Mohajeri-Tehrani MR, Samadi M, et al. Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients. Acta Diabetol. 2019;56(11):1199–1207. doi:10.1007/s00592-019-01374-x
   PubMed Web of Science ®Google Scholar
• Sporea I, Mare R, Popescu A, et al. Screening for liver fibrosis and steatosis in a large cohort of patients with type 2 diabetes using vibration controlled transient elastography and controlled attenuation parameter in a single-center real-life experience. J Clin Med. 2020;9(4):1032. doi:10.3390/jcm9041032
   PubMed Web of Science ®Google Scholar
• Tuong TTK, Tran DK, Phu PQT, et al. Non-alcoholic fatty liver disease in patients with type 2 diabetes: evaluation of hepatic fibrosis and steatosis using fibroscan. Diagnostics. 2020;10(3). doi:10.3390/diagnostics10030159
   Web of Science ®Google Scholar
• Zhao H, Song X, Li Z, Wang X. Risk factors associated with nonalcohol fatty liver disease and fibrosis among patients with type 2 diabetes mellitus. Medicine. 2018;97(37):e12356. doi:10.1097/MD.0000000000012356
   PubMed Web of Science ®Google Scholar
• Dai CY, Fang TJ, Hung WW, Tsai HJ, Tsai YC. The determinants of liver fibrosis in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus. Biomedicines. 2022;10(7):1487. doi:10.3390/biomedicines10071487
   PubMed Web of Science ®Google Scholar
• Mendez-Sanchez N, Cerda-Reyes E, Higuera-de-la-Tijera F, et al. Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis. F1000Res. 2020;9:56. doi:10.12688/f1000research.21918.1
   PubMedGoogle Scholar
• Chen K, Sng WK, Quah JH, et al. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus. PLoS One. 2020;15(8):e0236977. doi:10.1371/journal.pone.0236977
   PubMed Web of Science ®Google Scholar
• Browning MG, Khoraki J, DeAntonio JH, et al. Protective effect of black relative to white race against non-alcoholic fatty liver disease in patients with severe obesity, independent of type 2 diabetes. Int J Obes. 2018;42(4):926–929. doi:10.1038/ijo.2017.309
   Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325. doi:10.1002/hep.21178
   PubMed Web of Science ®Google Scholar
• Sun W, Cui H, Li N, et al. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study. Hepatol Res. 2016;46(9):862–870. doi:10.1111/hepr.12647
   PubMed Web of Science ®Google Scholar
• Tatoli R, Tirelli S, Lampignano L, et al. Liver fibrosis and hearing loss in an older mediterranean population: results from the salus in apulia study. J Clin Med. 2022;11(23):7213. doi:10.3390/jcm11237213
   PubMed Web of Science ®Google Scholar
• Sandhu S, Orsi C, Francis GL, et al. Shear wave elastography reveals a high prevalence of liver fibrosis in overweight or obese Hispanic youth. J Ultrason. 2020;20(82):e162–e168. doi:10.15557/JoU.2020.0027
   PubMed Web of Science ®Google Scholar
• Mikolasevic I, Domislovic V, Turk Wensveen T, et al. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study. Eur J Intern Med. 2020;82:68–75. doi:10.1016/j.ejim.2020.08.005
   PubMed Web of Science ®Google Scholar
• Kuchay MS, Choudhary NS, Mishra SK, et al. Prevalence of clinically relevant liver fibrosis due to nonalcoholic fatty liver disease in Indian individuals with type 2 diabetes. JGH Open. 2021;5(8):915–922. doi:10.1002/jgh3.12606
   PubMed Web of Science ®Google Scholar
• Alam MS, Kamrul-Hasan ABM, Kalam ST, et al. Liver stiffness measurement by using transient elastography in Bangladeshi patients with type 2 diabetes mellitus and ultrasonography-diagnosed nonalcoholic fatty liver disease. Diabetes Metab Syndr Obes. 2021;14:3089–3096. doi:10.2147/DMSO.S317876
   PubMed Web of Science ®Google Scholar
• Bril F, McPhaul MJ, Caulfield MP, et al. Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes. Diabetes Care. 2020;43(2):290–297. doi:10.2337/dc19-1071
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Chan WK, Piyachaturawat P, et al. Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study. BMC Gastroenterol. 2020;20(1):88. doi:10.1186/s12876-020-01240-z
   PubMed Web of Science ®Google Scholar
• Naguib M, Abou Elfotouh M, Wifi MN. Elevated serum cyclophilin D level is associated with nonalcoholic fatty liver disease and higher fibrosis scores in patients with diabetes mellitus. Int J Gen Med. 2021;14:4665–4675. doi:10.2147/IJGM.S322986
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Hirose S, Matsumoto K, Tatemichi M, et al. Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: lean versus overweight patients. PLoS One. 2020;15(11):e0241770. doi:10.1371/journal.pone.0241770
   PubMed Web of Science ®Google Scholar
• Petta S, Di Marco V, Pipitone RM, et al. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: genetic and metabolic risk factors in a general population. Liver Int. 2018;38(11):2060–2068. doi:10.1111/liv.13743
   PubMed Web of Science ®Google Scholar
• Han J, Wang Y, Yuan Z, et al. Nonalcoholic fatty liver disease represents a greater metabolic burden in patients with atherosclerosis: a cross-sectional study. Medicine. 2019;98(11):e14896. doi:10.1097/MD.0000000000014896
   PubMed Web of Science ®Google Scholar
• Zhao YC, Zhao GJ, Chen Z, et al. Nonalcoholic fatty liver disease: an emerging driver of hypertension. Hypertension. 2020;75(2):275–284. doi:10.1161/HYPERTENSIONAHA.119.13419
   PubMed Web of Science ®Google Scholar
• Lorbeer R, Bayerl C, Auweter S, et al. Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease. J Hypertens. 2017;35(4):737–744. doi:10.1097/HJH.0000000000001245
   PubMed Web of Science ®Google Scholar
• Granzow M, Schierwagen R, Klein S, et al. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology. 2014;60(1):334–348. doi:10.1002/hep.27117
   PubMed Web of Science ®Google Scholar
• Godoy-Lugo JA, Thorwald MA, Hui DY, et al. Chronic angiotensin receptor activation promotes hepatic triacylglycerol accumulation during an acute glucose challenge in obese-insulin-resistant OLETF rats. Endocrine. 2022;75(1):92–107. doi:10.1007/s12020-021-02834-7
   PubMed Web of Science ®Google Scholar
• Yuan Y, Naito H, Kitamori K, et al. The antihypertensive agent hydralazine reduced extracellular matrix synthesis and liver fibrosis in nonalcoholic steatohepatitis exacerbated by hypertension. PLoS One. 2020;15(12):e0243846. doi:10.1371/journal.pone.0243846
   PubMed Web of Science ®Google Scholar
• Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158(7):1851–1864. doi:10.1053/j.gastro.2020.01.052
   PubMed Web of Science ®Google Scholar
• Marquez-Exposito L, Tejedor-Santamaria L, Valentijn FA, et al. Oxidative stress and cellular senescence are involved in the aging kidney. Antioxidants. 2022;11(2). doi:10.3390/antiox11020301
   Web of Science ®Google Scholar
• Jaafar RF, Hajj Ali AM, Zaghal AM, et al. Fibroscan and low-density lipoprotein as determinants of severe liver fibrosis in diabetic patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2019;31(12):1540–1544. doi:10.1097/MEG.0000000000001461
   PubMed Web of Science ®Google Scholar
• Fujihara Y, Hamanoue N, Yano H, et al. High sex hormone-binding globulin concentration is a risk factor for high fibrosis-4 index in middle-aged Japanese men. Endocr J. 2019;66(7):637–645. doi:10.1507/endocrj.EJ18-0505
   PubMed Web of Science ®Google Scholar
• Ruschenbaum S, Schwarzkopf K, Friedrich-Rust M, et al. Patatin-like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events. Hepatol Commun. 2018;2(7):798–806. doi:10.1002/hep4.1183
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Nakahara T, Ono M, et al. Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease. J Gastroenterol Hepatol. 2021;36:2275–2284. doi:10.1111/jgh.15487
   PubMedGoogle Scholar
• Honda F, Hiramatsu A, Hyogo H, et al. Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring. PLoS One. 2018;13(4):e0195028. doi:10.1371/journal.pone.0195028
   PubMed Web of Science ®Google Scholar
• Mendes FD, Suzuki A, Sanderson SO, Lindor KD, Angulo P. Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2012;10(9):1028–1033 e1022. doi:10.1016/j.cgh.2012.05.008
   PubMed Web of Science ®Google Scholar
• Inoue K, Goto A, Kishimoto M, et al. Possible discrepancy of HbA1c values and its assessment among patients with chronic renal failure, hemodialysis and other diseases. Clin Exp Nephrol. 2015;19(6):1179–1183. doi:10.1007/s10157-015-1110-6
   PubMed Web of Science ®Google Scholar
• Yoo JH, Kang M, Kim G, et al. Mean and visit-to-visit variability of glycated hemoglobin, and the risk of non-alcoholic fatty liver disease. J Diabetes Investig. 2021;12(7):1252–1262. doi:10.1111/jdi.13455
   PubMed Web of Science ®Google Scholar
• Tanaka K, Takahashi H, Hyogo H, et al. Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non-alcoholic fatty liver disease. Hepatol Res. 2019;49(3):296–303. doi:10.1111/hepr.13282
   PubMed Web of Science ®Google Scholar
• Kamalraj N, Sathishkumar M, Arunvignesh M, et al. Retrospective analysis (2009–2017) of factors associated with progression and regression of non-alcoholic fatty liver disease (Hepatic steatosis) in patients with type 2 diabetes seen at a tertiary diabetes centre in Southern India. Diabetes Metab Syndr. 2021;15(5):102261. doi:10.1016/j.dsx.2021.102261
   PubMed Web of Science ®Google Scholar
• Fernando JN, Alba RL, Alba W. Factors associated with the severity of findings on hepatic transient elastography among persons with type 2 diabetes and fatty liver. J ASEAN Fed Endocr Soc. 2019;34(2):134–143. doi:10.15605/jafes.034.02.03
   PubMedGoogle Scholar
• Alexopoulos AS, Crowley MJ, Wang Y, et al. Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease. Hepatology. 2021;74(3):1220–1233. doi:10.1002/hep.31806
   PubMed Web of Science ®Google Scholar
• Mantovani A, Zusi C, Csermely A, et al. Association between lower plasma adiponectin levels and higher liver stiffness in type 2 diabetic individuals with nonalcoholic fatty liver disease: an observational cross-sectional study. Hormones. 2022;21:477–486. doi:10.1007/s42000-022-00387-6
   PubMedGoogle Scholar
• Koo DJ, Lee MY, Jung I, et al. Changes in insulin resistance index and the risk of liver fibrosis in patients with nonalcoholic fatty liver disease without diabetes: Kangbuk Samsung health study. Endocrinol Metab. 2021;36(5):1016–1028. doi:10.3803/EnM.2021.1110
   Google Scholar
• Koo DJ, Lee MY, Jung I, et al. Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: a cohort study. PLoS One. 2021;16(8):e0255535. doi:10.1371/journal.pone.0255535
   PubMed Web of Science ®Google Scholar
• Aller R, Siguenza R, Pina M, et al. Insulin resistance is related with liver fibrosis in type 2 diabetic patients with non-alcoholic fatty liver disease proven biopsy and Mediterranean diet pattern as a protective factor. Endocrine. 2020;68(3):557–563. doi:10.1007/s12020-020-02268-7
   PubMed Web of Science ®Google Scholar